Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:22:33 EDT Thu 20 Mar 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:EXEL - EXELIXIS INC - https://www.exelixis.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
EXEL - Q0.437.19·37.210.237.21+0.150.41,554.256,85816,84236.99  37.63  36.95540.00  20.1414:03:02Feb 2515 min RT 2¢

Recent Trades - Last 10 of 16842
Time ETExPriceChangeVolume
14:03:12Q37.210.1525
14:03:10Q37.21990.15992
14:03:05Q37.21970.1597100
14:03:02Q37.22080.16083
14:03:00Q37.210.15100
14:02:57Q37.200.1450
14:02:57Q37.200.1410
14:02:56Q37.190.13100
14:02:54Q37.22180.16182
14:02:54Q37.21340.15349

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-02-25 16:05U:EXELNews ReleaseExelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March
2025-02-20 17:05U:EXELNews ReleaseExelixis Announces a Newly Authorized $500 Million Stock Repurchase Program
2025-02-15 11:10U:EXELNews ReleaseExelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX(TM) (cabozantinib) in Combination with Opdivo(TM) (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025
2025-02-13 16:05U:EXELNews ReleaseExelixis to Participate in the Citi 2025 Virtual Oncology Leadership Summit
2025-02-11 16:05U:EXELNews ReleaseExelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update
2025-01-28 16:05U:EXELNews ReleaseExelixis to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025
2025-01-25 10:00U:EXELNews ReleaseExelixis Announces Encouraging Results from Phase 1b/2 STELLAR-001 Trial Evaluating Zanzalintinib Alone or in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer at ASCO GI 2025
2025-01-24 14:30U:EXELNews ReleaseExelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Study Evaluating Cabozantinib in Advanced Gastrointestinal Neuroendocrine Tumors Presented at ASCO GI 2025
2025-01-12 16:00U:EXELNews ReleaseExelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025
2025-01-09 09:00U:EXELNews ReleaseExelixis Provides Update on Oncologic Drugs Advisory Committee Meeting for Cabozantinib (CABOMETYX(TM)) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
2025-01-06 16:05U:EXELNews ReleaseExelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
2024-11-27 16:05U:EXELNews ReleaseExelixis to Webcast Fireside Chats as Part of Investor Conferences in December
2024-11-26 16:05U:EXELNews ReleaseExelixis Provides Regulatory Update Related to Supplemental New Drug Application for Cabozantinib (CABOMETYX(TM)) for the Treatment of Patients with Previously Treated Advanced Neuroendocrine Tumors
2024-11-07 16:05U:EXELNews ReleaseExelixis to Webcast Fireside Chats as Part of Investor Conferences in November
2024-10-29 16:05U:EXELNews ReleaseExelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update
2024-10-15 16:05U:EXELNews ReleaseExelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
2024-10-15 13:57U:EXELNews ReleaseExelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
2024-10-14 08:00U:EXELNews ReleaseExelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA(TM) (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG(TM) (belzutifan) in Renal Cell Carcinoma
2024-10-09 08:30U:EXELNews ReleaseONCOLOGY COMMERCIALIZATION LEADER P.J. HALEY TO JOIN NETRAMARK BOARD OF DIRECTORS
2024-09-16 08:45U:EXELNews ReleaseExelixis Announces Final Results from Phase 3 Pivotal CABINET Study Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2024 and Published in New England Journal of Medicine